C-CAR011 Treatment in Subjects With ALL After HSCT

Inclusion Criteria:

* Age 15-65 years old, male or female.
* Volunteered to participate in this study and signed informed consent.
* Meet the two populations above.
* Histologically diagnosed as CD19+B-ALL.
* 100% T lymphocytes of donor.
* Treatment without chemotherapy and antibody therapy within 2 weeks prior to C-CAR011 therapy.
* Left ventricular ejection fraction (LVEF) ≧ 50%, no evidence of pericardial effusion and clinically significant arrhythmias.
* Baseline oxygen saturation ≧ 92% on room air and with normal pulmonary function, no evidence of active lung infection.
* Expected survival ≧ 3 months.
* Eastern cooperative oncology group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

* History of allergy to cellular products.
* Any kind of these laboratory testing: serum total bilirubin≧2.0mg/dl, serum albumin\<35g/L, ALT, AST≧3×ULN, serum creatinine≧2.0mg/ dl,platelets\<20×109/L.
* The subjects had active aGVHD with II-IV degrees (Glucksberg degrees) or active moderate to severe cGVHD.
* Severe uncontrolled infection (mycotic, bacterial, virus and so on).
* Any central nervous system leukemia(CNS2, CNS3) , with insensitive to intrathecal injection of or radiotherapy of head/spine; but effectively controlled cases will be eligible.
* The subjects were treated CART cells or DLI after HSCT.
* Bone marrow failure syndrome（BMF） after allogeneic hematopoietic stem cell transplantation.
* Any genetically modified T cell therapy.
* History of heavy drinking, drug taking or mental disease.
* Participated in any other clinical trial within one month prior to enrollment.
* Women who are pregnant or lactating or have breeding intent in 6 months.
* The investigators believe that any increase in the risk of the subject or interference with the results of the trial.